Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Heta trenden: Svenske eToro-profilen har avkastat 16,5 procent per år – här är hans tio största innehav

Analyser av Optomed

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Optomed: Strong H2 ahead - Redeye

Redeye interviewed Optomed’s CEO, Juho Himberg, following the company’s Q2 2026 report.

Redeye • 21 aug 07:08

Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control - Redeye

Redeye provides a research update following Optomed’s Q2 2026 report.

Redeye • 18 aug 11:48

Optomed: Solid device order - Redeye

Redeye views Optomed’s cEUR1.8m order from a US-based screening service provider and distributor positively.

Redeye • 22 jun 14:23

Optomed (Q1 Review): Soft sales weigh on sentiment - Redeye

Redeye provides a research update after Optomed’s Q1 2026 report.

Redeye • 07 maj 07:07

Optomed (Q1 Initial take): Softer quarter than expected - Redeye

Redeye provides an initial take following the release of Optomed’s Q1 2026 report.

Redeye • 06 maj 08:53

Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance - Redeye

Redeye provides a research update after Optomed’s Q4 2025 report.

Redeye • 11 feb 07:23

Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost - Redeye

Redeye provides an initial take following the release of Optomed’s Q4 2025 report.

Redeye • 10 feb 10:25

Optomed: Partnership with Aireen and AI integration approval for Lumo - Redeye

Redeye is positive about Optomed’s partnership with Aireen and the EU approval for AI integration with the Lumo camera.

Redeye • 12 jan 13:29

Optomed: Directed share issue announcement - Redeye

Redeye comments on Optomed’s directed share issue, raising EUR6.

Redeye • 11 dec 2025 10:59

Optomed Q3 (Review): Solid growth with a positive devices segment development - Redeye

Redeye provides an update following Optomed’s Q3 2025 report.

Redeye • 07 nov 2025 09:50

Optomed Q3 (Initial take): Solid report, supported by strong devices segment sales - Redeye

Redeye provides an initial take following the release of Optomed’s Q3 2025 report.

Redeye • 06 nov 2025 09:34

Optomed Q2: Soft Q2 sales raises the stakes for H2 recovery - Redeye

Redeye provides an update following Optomed’s Q2 2025 report.

Redeye • 08 aug 2025 07:24

Optomed Q2: Initial take – Softer sales than expected, but costs in line - Redeye

Redeye provides an initial take following the release of Optomed’s Q2 2025 report.

Redeye • 07 aug 2025 08:59

Optomed: Optomed Lumo launch - Redeye

Redeye is positive about Optomed´s launch of its next-gen camera, Optomed Lumo.

Redeye • 05 jun 2025 13:57

Optomed Q1: A solid start to the year - Redeye

Redeye provides an update following Optomed’s Q1 2025 report.

Redeye • 07 maj 2025 07:17

Optomed Q1: Initial take – Solid performance by the Devices segment - Redeye

Redeye provides an initial take following the release of Optomed’s Q1 2025 report.

Redeye • 06 maj 2025 11:20

Optomed Q4: Quarter in line with expectations - Redeye

Redeye provides an update following Optomed’s Q4 report.

Redeye • 14 feb 2025 07:12

Optomed Q4: Initial take – Sales in line and slightly higher costs than expected - Redeye

Redeye provides an initial take following the release of Optomed’s Q4 2024 report.

Redeye • 13 feb 2025 10:45

Optomed: Expects full-year 2024 sales in line with 2023 - Redeye

Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate accordingly.

Redeye • 12 nov 2024 07:27

Optomed Q3: In line with the expectations - Redeye

Redeye provides an update following Optomed’s Q3 report.

Redeye • 08 nov 2024 10:28

Optomed Q3: Initial take – Soft sales as expected - Redeye

Redeye provides an initial take following the release of Optomed’s Q3 2024 report.

Redeye • 07 nov 2024 10:31

Optomed: Decreased full-year outlook - Redeye

Redeye comments on Optomed’s profit warning, where the company expects its revenues to decrease compared to 2023.

Redeye • 26 sep 2024 14:04

Optomed Q2: Soft sales and important quarters ahead - Redeye

Redeye provides an update following Optomed’s Q2 report.

Redeye • 09 aug 2024 07:20

Optomed Q2: Initial take – Lower sales and EBIT than expected - Redeye

Redeye notes that Q2 sales and EBIT were lower than anticipated.

Redeye • 08 aug 2024 09:01

Optomed: Directed share issue - Redeye

Redeye comments on Optomed’s directed share issue, raising approximately EUR7.

Redeye • 27 jun 2024 10:07

Optomed Q1: Eyes on the US - Redeye

Redeye provides an update following Optomed’s FDA clearance for Aurora AEYE and the company’s Q1 report.

Redeye • 08 maj 2024 09:13

Optomed Q1: Initial take – Softer sales than expected, but EBIT in line - Redeye

Redeye notes that Q1 sales were slightly lower than our estimates; however, EBIT aligned with our forecast.

Redeye • 07 maj 2024 09:23

Optomed: FDA clearance for Aurora AEYE - Redeye

Redeye endorses Optomed and AEYE Health’s FDA (510k) clearance of Aurora AEYE.

Redeye • 02 maj 2024 07:10

Optomed Q4: Lower sales than anticipated, but a major catalyst is getting closer - Redeye

Redeye provides an update in relation to Optomed’s Q4 2023 report.

Redeye • 16 feb 2024 07:35

Optomed Q4: Initial take – Sales came in lower than expected - Redeye

Redeye provides an initial take on Optomed’s Q4 2023 report.

Redeye • 15 feb 2024 08:55

Optomed Q3: Solid quarter from both the software and devices segment - Redeye

Redeye provides an update in relation to Optomed’s Q3 2023 report.

Redeye • 06 nov 2023 07:07

Optomed Q3 2023: Better than expected - Redeye

Redeye provides an initial take on Optomed’s Q3 2023 report.

Redeye • 03 nov 2023 09:02

Optomed: Directed share issue - Redeye

Redeye comments on Optomed’s directed share issue, raising EUR4.

Redeye • 21 sep 2023 10:55

Optomed Q2 2023: Waiting game - Redeye

Redeye provides an update in relation to Optomed’s Q2 2023 report.

Redeye • 07 aug 2023 08:13

Optomed: Q2 2023 initial take - Redeye

Redeye provides an initial take on Optomed’s Q2 2023 report.

Redeye • 04 aug 2023 08:59

Optomed: AI partnership with Thirona Retina - Redeye

Redeye comments on Optomed’s announcement regarding its new AI partnership with Thirona Retina.

Redeye • 09 maj 2023 10:33

Optomed Q1 2023: Delivers as expected - Redeye

Redeye provides an update in relation to Optomed’s Q1 2023 report.

Redeye • 05 maj 2023 14:28

Optomed: Q1 2023 initial take - Redeye

Redeye provides an initial take on Optomed’s Q1 2023 report.

Redeye • 05 maj 2023 09:01

Optomed Q4 2022: In line with our expectations - Redeye

Redeye provides an update in relation to Optomed’s Q4 2022 report.

Redeye • 20 feb 2023 08:14

Optomed: Initial take on Q4 2022 results - Redeye

Redeye provides an initial take on Optomed’s Q4 2022 report.

Redeye • 17 feb 2023 09:11

Optomed: Directed share issue - Redeye

Redeye comments on Optomed’s directed share issue, raising EUR4.

Redeye • 12 dec 2022 11:22

Optomed Q3 2022: Western sales channels compensate for uncertainties in China - Redeye

Redeye provides its comments on Optomed’s Q3 2022 report.

Redeye • 03 nov 2022 12:45

Optomed: Comment on the decreased full-year outlook - Redeye

Redeye provides a short comment on Optomed’s decreased full-year outlook.

Redeye • 27 okt 2022 15:53

Optomed: Keep an Eye on Optomed - Redeye

Redeye still regards Optomed’s current share price levels as an attractive long-term entry point, following its case review (prompted by a c...

Redeye • 23 aug 2022 07:16

Optomed: Q2’22 Report Comment - Redeye

Redeye provides its comments on Optomed’s Q2’22 report.

Redeye • 04 aug 2022 11:01

Optomed Q1: Investment case intact - Redeye

Redeye maintains its valuation of Optomed after the Q1 report.

Redeye • 06 maj 2022 15:40

Optomed Q4: US and Europe new strategic markets - Redeye

Redeye maintains its positive view and valuation of Optomed.

Redeye • 18 feb 2022 07:52

Optomed: Adjusted revenue estimates - Redeye

Redeye revises slightly its revenue and EBITDA projections for 2021.

Redeye • 14 jul 2021 07:31